Fibrosi polmonare idiopatica (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fibrosi polmonare idiopatica" in Italian language version.

refsWebsite

Global rank Italian rank

43nih.gov

4^th place

9^th place

23doi.org

2^nd place

7^th place

18oadoi.org

799^th place

22^nd place

13archive.org

6^th place

8^th place

2intermune.com

low place

1europa.eu

68^th place

57^th place

1omim.org

4,380^th place

4,368^th place

1doai.io

low place

3,405^th place

1web.archive.org

1^st place

1boehringer-ingelheim.com

low place

1coalitionforipf.org

low place

1akcchf.org

low place

akcchf.org

Canine Pulmonary Fibrosis.[4] Akcchf.org. Retrieved 2013-04-11.

archive.org

Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ, Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK, in Thorax, vol. 61, n. 11, 2006, pp. 980-985, PMC 2121155, PMID 16844727.
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB, The rising incidence of idiopathic pulmonary fibrosis in the U.K, in Thorax, vol. 66, n. 6, 2011, pp. 462-467, DOI:10.1136/thx.2010.148031, PMID 21525528.
Olson AL, Swigris JJ, Idiopathic pulmonary fibrosis: diagnosis and epidemiology, in Clinics in chest medicine, vol. 33, n. 1, 2012, pp. 41–50, DOI:10.1016/j.ccm.2011.12.001, PMID 2236524.
Pardo A, Selman M, Idiopathic pulmonary fibrosis: new insights in its pathogenesis, in Int J Biochem Cell Biol., vol. 34, n. 12, 2002, pp. 1534–1538.
Baughman RP, Shipley RT, Loudon RG, Lower EE, Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis, in Chest, vol. 100, n. 1, 1991, pp. 96-101, PMID 2060395.
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, et al., Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model, in Chest, vol. 145, n. 4, 2014, pp. 723–728, PMID 24114524.
Russo MJ, Iribarne A, Hong KN, Davies RR, Xydas S, Takayama H, Ibrahimiye A, Gelijns AC, Bacchetta MD, D'Ovidio F, Arcasoy S, Sonett JR, High lung allocation score is associated with increased morbidity and mortality following transplantation, in Chest, vol. 137, n. 3, 2010, pp. 651-657.
George TJ, Arnaoutakis GJ, Shah AS, Lung transplantation for idiopathic pulmonary fibrosis, in Ann Thorac Surg., vol. 84, n. 4, 2007, pp. 1121–1128, PMID 17888957.
Morrison DA, Stovall JR., Increased exercise capacity in hypoxemic patients after long-term oxygen therapy, in Chest, vol. 102, n. 2, 1992, pp. 542-550, PMID 1643945.
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR, Depression and functional status are strongly associated with dyspnea in interstitial lung disease, in Chest, vol. 139, n. 3, 2011, pp. 609-616.
Stern JB, Mal H, Groussard O, Brugière O, Marceau A, Jebrak G, Fournier M, Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure, in Chest, vol. 120, n. 1, 2001, pp. 213-219.
Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G, Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect, in Chest, vol. 125, n. 6, 2004, pp. 2278–2288, PMID 15189952.
Webb JA, Armstrong J, Chronic idiopathic pulmonary fibrosis in a West Highland white terrier, in Can Vet J., vol. 43, n. 9, 2002, pp. 703–705, PMC 339552, PMID 12240528.

boehringer-ingelheim.com

us.boehringer-ingelheim.com

Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation. Press release. Retrieved 2014-04-08: [2]

coalitionforipf.org

[3]^{[collegamento interrotto]}

doai.io

Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L, Non-steroid agents for idiopathic pulmonary fibrosis, in Cochrane Database Syst Rev, n. 9, 2010, pp. 821-829, DOI:10.1002/14651858.CD003134.pub2.

doi.org

dx.doi.org

Raghu G, Collard HR, Egan JJ, et al., An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management, in Am J Respir Crit Care Med, vol. 183, n. 6, 2011, pp. 788–824, DOI:10.1164/rccm.2009-040GL, PMID 21471066.
Meltzer EB, Noble PW, Idiopathic pulmonary fibrosis, in Orphanet J Rare Dis, vol. 3, n. 1, 2008, DOI:10.1186/1750-1172-3-8, PMC 2330030, PMID 18366757.
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB, The rising incidence of idiopathic pulmonary fibrosis in the U.K, in Thorax, vol. 66, n. 6, 2011, pp. 462-467, DOI:10.1136/thx.2010.148031, PMID 21525528.
Olson AL, Swigris JJ, Idiopathic pulmonary fibrosis: diagnosis and epidemiology, in Clinics in chest medicine, vol. 33, n. 1, 2012, pp. 41–50, DOI:10.1016/j.ccm.2011.12.001, PMID 2236524.
Williams KJ, Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents, in Veterinary Pathology, vol. 51, n. 2, 2014, pp. 372–384, DOI:10.1177/0300985814521838, PMID 24569614.
Harari S, Caminati A, IPF: new insight on pathogenesis and treatment, in Allergy, vol. 65, n. 5, 2010, pp. 537–553, DOI:10.1111/j.1398-9995.2009.02305, PMID 20121758.
Loomis-King H, Flaherty KR, Moore BB, Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis, in Curr. Opin. Pharmacol., vol. 13, n. 3, aprile 2013, pp. 377-385, DOI:10.1016/j.coph.2013.03.015.
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?, in Am J Respir Crit Care Med., vol. 170, n. 8, 2004, pp. 904-910, DOI:10.1164/rccm.200402-147OC, PMID 15256390.
Cottin V, Cordier JF, Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis, in Eur Respir J., vol. 40, n. 3, 2012, pp. 519-521, DOI:10.1183/09031936.00001612, PMID 22941541.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al., Interpretative strategies for lung function tests, in Eur Respir J., vol. 26, n. 5, 2005, pp. 948–968, DOI:10.1183/09031936.05.00035205, PMID 16264058.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, in Lancet, vol. 377, n. 9779, 2011, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, et al. IPF study group, The clinical course of patients with idiopathic pulmonary fibrosis, in Ann Intern Med., vol. 377, n. 9779, 2005, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
Kim DS, Collard HR, King TE, Classification and natural history of the idiopathic interstitial pneumonias, in Proc Am Thorac Soc., vol. 3, n. 4, 2006, pp. 285-292, DOI:10.1513/pats.200601-005TK, PMC 2658683, PMID 1673819.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, et al. INSPIRE Study Group, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis, in Lancet, vol. 374, n. 9685, 2009, pp. 222-228, DOI:10.1016/S0140-6736(09)60551-1, PMID 19570573.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, et al., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 184, n. 1, 2011, pp. 92-99, DOI:10.1164/rccm.201011-1874OC, PMID 21474646.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, et al., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial, in Ann Intern Med., vol. 158, n. 9, 2013, pp. 641-649, DOI:10.7326/0003-4819-158-9-201305070-00003, PMID 23648946.
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 186, n. 1, 2012, pp. 88-95, DOI:10.1164/rccm.201202-0314OC, PMID 22561965.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, et al., Pirfenidone in idiopathic pulmonary fibrosis, in Eur Respir J., vol. 35, n. 4, 2010, pp. 821-829, DOI:10.1183/09031936.00005209, PMID 19996196.
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L, Non-steroid agents for idiopathic pulmonary fibrosis, in Cochrane Database Syst Rev, n. 9, 2010, pp. 821-829, DOI:10.1002/14651858.CD003134.pub2.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al., High-dose acetylcysteine in idiopathic pulmonary fibrosis, in N Engl J Med., vol. 353, n. 21, 2005, pp. 2229–2242, DOI:10.1056/NEJMoa042976, PMID 16306520.
Behr J., Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis, in N Engl J Med., vol. 367, n. 9, 2012, pp. 869–871, DOI:10.1056/NEJMc1207471, PMID 22931324.
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G, Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years, in Transplant Proc., vol. 41, n. 1, 2009, pp. 289–291, DOI:10.1016/j.transproceed.2008.10.042, PMID 19249537.
Kenn K, Gloeckl R, Behr J, Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review, in Respiration; international review of thoracic diseases, vol. 86, n. 2, 2013, pp. 89–99, DOI:10.1159/000354112, PMID 23942353.

europa.eu

epp.eurostat.ec.europa.eu

Eurostat News Release. European demography. 110/2010. 27 July 2010

intermune.com

investor.intermune.com

InterMune Receives FDA Breakthrough Therapy Designation for Pirfenidone, an Investigational Treatment for IPF, Press release. Retrieved 2014-04-08:http://investor.intermune.com/phoenix.zhtml?c=100067&p=irol-newsArticle&ID=1948523&highlight=.
InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States., Press release. Retrieved 2014-04-08:http://investor.intermune.com/phoenix.zhtml?c=100067&p=irol-newsArticle&ID=1931863&highlight=.

nih.gov

ncbi.nlm.nih.gov

Raghu G, Collard HR, Egan JJ, et al., An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management, in Am J Respir Crit Care Med, vol. 183, n. 6, 2011, pp. 788–824, DOI:10.1164/rccm.2009-040GL, PMID 21471066.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, This official statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was approved by the ATS board of directors, June 2013 and by the ERS Steering Committee, March 2013, in Am Respir Crit Care Med, vol. 188, n. 6, 2013, pp. 733-748, PMID 24032382.
Meltzer EB, Noble PW, Idiopathic pulmonary fibrosis, in Orphanet J Rare Dis, vol. 3, n. 1, 2008, DOI:10.1186/1750-1172-3-8, PMC 2330030, PMID 18366757.
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ, Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK, in Thorax, vol. 61, n. 11, 2006, pp. 980-985, PMC 2121155, PMID 16844727.
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB, The rising incidence of idiopathic pulmonary fibrosis in the U.K, in Thorax, vol. 66, n. 6, 2011, pp. 462-467, DOI:10.1136/thx.2010.148031, PMID 21525528.
Hyldgaard C, Hilberg O, Muller A, Bendstrup E, A cohort study of interstitial lung diseases in central Denmark, in Respir Med, vol. 108, n. 5, 2014, pp. 793–799, PMID 24636811.
Olson AL, Swigris JJ, Idiopathic pulmonary fibrosis: diagnosis and epidemiology, in Clinics in chest medicine, vol. 33, n. 1, 2012, pp. 41–50, DOI:10.1016/j.ccm.2011.12.001, PMID 2236524.
Williams KJ, Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents, in Veterinary Pathology, vol. 51, n. 2, 2014, pp. 372–384, DOI:10.1177/0300985814521838, PMID 24569614.
García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, Loyd JE, Selman M. Buendía-Roldán I, Fernández-Plata MR, et al., Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis, in Respir Med., vol. 105, n. 12, 2011, pp. 1902–1990, PMID 21917441.
Harari S, Caminati A, IPF: new insight on pathogenesis and treatment, in Allergy, vol. 65, n. 5, 2010, pp. 537–553, DOI:10.1111/j.1398-9995.2009.02305, PMID 20121758.
Selman M, King TE, Pardo A, Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy, in Ann Intern Med., vol. 134, n. 2, 2001, pp. 136–151, PMID 11177318.
Mathai S, et al., Genetic susceptibility and pulmonary fibrosis, in Curr Opin Pulm Med, vol. 20, n. 5, 2014, pp. 429–435, PMID 25022318.
Kropski JA, Mitchell DB, Markin C, et al., A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia, in Chest, 2014, PMID 24504062.
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?, in Am J Respir Crit Care Med., vol. 170, n. 8, 2004, pp. 904-910, DOI:10.1164/rccm.200402-147OC, PMID 15256390.
Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?, in Am J Respir Crit Care Med., vol. 175, n. 10, 2007, pp. 1054–1060, PMC 1899268, PMID 17255566.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al., Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia, in Am J Respir Crit Care Med., vol. 168, n. 5, 2007, pp. 543-548, PMID 12773329.
Cottin V, Cordier JF, Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis, in Eur Respir J., vol. 40, n. 3, 2012, pp. 519-521, DOI:10.1183/09031936.00001612, PMID 22941541.
Baughman RP, Shipley RT, Loudon RG, Lower EE, Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis, in Chest, vol. 100, n. 1, 1991, pp. 96-101, PMID 2060395.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al., Interpretative strategies for lung function tests, in Eur Respir J., vol. 26, n. 5, 2005, pp. 948–968, DOI:10.1183/09031936.05.00035205, PMID 16264058.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, in Lancet, vol. 377, n. 9779, 2011, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, et al. IPF study group, The clinical course of patients with idiopathic pulmonary fibrosis, in Ann Intern Med., vol. 377, n. 9779, 2005, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, for the ASCEND Study Group., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, in N Engl J Med, vol. 370, n. 22, 2014, pp. 2083–2092, PMID 24836312.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, M Costabel U, Cottin V, Flaherty KR, for the INPULSIS Trial Investigators., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, in N Engl J Med, vol. 370, n. 22, 2014, pp. 2071–2082, PMID 24836310.
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP, Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 157, n. 1, 1998, pp. 199-203, PMID 9445300.
Kim DS, Collard HR, King TE, Classification and natural history of the idiopathic interstitial pneumonias, in Proc Am Thorac Soc., vol. 3, n. 4, 2006, pp. 285-292, DOI:10.1513/pats.200601-005TK, PMC 2658683, PMID 1673819.
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, et al., Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model, in Chest, vol. 145, n. 4, 2014, pp. 723–728, PMID 24114524.
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, et al., Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis, in JAMA, vol. 309, n. 21, 2013, pp. 2232–2239, PMID 23695349.
Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al., Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis, in Thorax, vol. 68, n. 5, 2013, pp. 436–441, PMID 23321605.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, et al. INSPIRE Study Group, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis, in Lancet, vol. 374, n. 9685, 2009, pp. 222-228, DOI:10.1016/S0140-6736(09)60551-1, PMID 19570573.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, et al., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 184, n. 1, 2011, pp. 92-99, DOI:10.1164/rccm.201011-1874OC, PMID 21474646.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, et al., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial, in Ann Intern Med., vol. 158, n. 9, 2013, pp. 641-649, DOI:10.7326/0003-4819-158-9-201305070-00003, PMID 23648946.
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 186, n. 1, 2012, pp. 88-95, DOI:10.1164/rccm.201202-0314OC, PMID 22561965.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, et al., Pirfenidone in idiopathic pulmonary fibrosis, in Eur Respir J., vol. 35, n. 4, 2010, pp. 821-829, DOI:10.1183/09031936.00005209, PMID 19996196.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al., High-dose acetylcysteine in idiopathic pulmonary fibrosis, in N Engl J Med., vol. 353, n. 21, 2005, pp. 2229–2242, DOI:10.1056/NEJMoa042976, PMID 16306520.
Behr J., Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis, in N Engl J Med., vol. 367, n. 9, 2012, pp. 869–871, DOI:10.1056/NEJMc1207471, PMID 22931324.
The Idiopathic Pulmonary Fibrosis Clinical Research Network, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, in N Engl J Med., vol. 370, n. 22, 2014, pp. 2093–2102, PMID 24836309.
George TJ, Arnaoutakis GJ, Shah AS, Lung transplantation for idiopathic pulmonary fibrosis, in Ann Thorac Surg., vol. 84, n. 4, 2007, pp. 1121–1128, PMID 17888957.
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G, Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years, in Transplant Proc., vol. 41, n. 1, 2009, pp. 289–291, DOI:10.1016/j.transproceed.2008.10.042, PMID 19249537.
Morrison DA, Stovall JR., Increased exercise capacity in hypoxemic patients after long-term oxygen therapy, in Chest, vol. 102, n. 2, 1992, pp. 542-550, PMID 1643945.
Kenn K, Gloeckl R, Behr J, Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review, in Respiration; international review of thoracic diseases, vol. 86, n. 2, 2013, pp. 89–99, DOI:10.1159/000354112, PMID 23942353.
Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G, Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect, in Chest, vol. 125, n. 6, 2004, pp. 2278–2288, PMID 15189952.
Webb JA, Armstrong J, Chronic idiopathic pulmonary fibrosis in a West Highland white terrier, in Can Vet J., vol. 43, n. 9, 2002, pp. 703–705, PMC 339552, PMID 12240528.

nih.gov

Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful [1], Nih.gov., Retrieved 2013-04-11

oadoi.org

Raghu G, Collard HR, Egan JJ, et al., An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management, in Am J Respir Crit Care Med, vol. 183, n. 6, 2011, pp. 788–824, DOI:10.1164/rccm.2009-040GL, PMID 21471066.
Williams KJ, Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents, in Veterinary Pathology, vol. 51, n. 2, 2014, pp. 372–384, DOI:10.1177/0300985814521838, PMID 24569614.
Harari S, Caminati A, IPF: new insight on pathogenesis and treatment, in Allergy, vol. 65, n. 5, 2010, pp. 537–553, DOI:10.1111/j.1398-9995.2009.02305, PMID 20121758.
Loomis-King H, Flaherty KR, Moore BB, Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis, in Curr. Opin. Pharmacol., vol. 13, n. 3, aprile 2013, pp. 377-385, DOI:10.1016/j.coph.2013.03.015.
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?, in Am J Respir Crit Care Med., vol. 170, n. 8, 2004, pp. 904-910, DOI:10.1164/rccm.200402-147OC, PMID 15256390.
Cottin V, Cordier JF, Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis, in Eur Respir J., vol. 40, n. 3, 2012, pp. 519-521, DOI:10.1183/09031936.00001612, PMID 22941541.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al., Interpretative strategies for lung function tests, in Eur Respir J., vol. 26, n. 5, 2005, pp. 948–968, DOI:10.1183/09031936.05.00035205, PMID 16264058.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, in Lancet, vol. 377, n. 9779, 2011, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, et al. IPF study group, The clinical course of patients with idiopathic pulmonary fibrosis, in Ann Intern Med., vol. 377, n. 9779, 2005, pp. 1760–1769, DOI:10.1016/S0140-6736(11)60405-4, PMID 21571362.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, et al. INSPIRE Study Group, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis, in Lancet, vol. 374, n. 9685, 2009, pp. 222-228, DOI:10.1016/S0140-6736(09)60551-1, PMID 19570573.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, et al., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 184, n. 1, 2011, pp. 92-99, DOI:10.1164/rccm.201011-1874OC, PMID 21474646.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, et al., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial, in Ann Intern Med., vol. 158, n. 9, 2013, pp. 641-649, DOI:10.7326/0003-4819-158-9-201305070-00003, PMID 23648946.
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 186, n. 1, 2012, pp. 88-95, DOI:10.1164/rccm.201202-0314OC, PMID 22561965.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, et al., Pirfenidone in idiopathic pulmonary fibrosis, in Eur Respir J., vol. 35, n. 4, 2010, pp. 821-829, DOI:10.1183/09031936.00005209, PMID 19996196.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al., High-dose acetylcysteine in idiopathic pulmonary fibrosis, in N Engl J Med., vol. 353, n. 21, 2005, pp. 2229–2242, DOI:10.1056/NEJMoa042976, PMID 16306520.
Behr J., Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis, in N Engl J Med., vol. 367, n. 9, 2012, pp. 869–871, DOI:10.1056/NEJMc1207471, PMID 22931324.
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G, Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years, in Transplant Proc., vol. 41, n. 1, 2009, pp. 289–291, DOI:10.1016/j.transproceed.2008.10.042, PMID 19249537.
Kenn K, Gloeckl R, Behr J, Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review, in Respiration; international review of thoracic diseases, vol. 86, n. 2, 2013, pp. 89–99, DOI:10.1159/000354112, PMID 23942353.

omim.org

Online 'Mendelian Inheritance in Man' (OMIM) 178500

web.archive.org

BIBF 1120 Fact Sheet. Retrieved 2014-04-08 (PDF), su dl.groovygecko.net. URL consultato il 27 settembre 2014 (archiviato dall'url originale il 3 marzo 2016).